TheraRadar
← Back
Data updated: Jun 12, 2026

MAP77

Pharma
Pharmaceuticals

MAP77 is a pharmaceutical company with 1 FDA-approved products.

2026
Since
1
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
1 Small Molecules

MAP77's Key Drugs

MAP77's core commercial portfolio centers on ATONCY — its most strategically important drugs approved in the last 15 years.

ATONCY
Approved 2026

MAP77's Recent FDA Approvals

MAP77 secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

ATONCY NDA
2026-03-20
atomoxetine hydrochloride
1 INDICATIONS AND USAGE ATONCY is indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adult and pediatric patients 6 years of age and older. ATONCY is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with ADHD. ATONCY is a selective norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of ADHD in adults and pediatric patients 6 years of age and older. ( 1 )

MAP77's Therapeutic Areas

Disease areas where MAP77 has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

MAP77 Pipeline Snapshot

Active clinical trials for MAP77 across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • ATONCY leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling